UK biotechnology company TRIMTECH Therapeutics announced on Monday that it has entered into a strategic research collaboration, option and licence agreement with Biogen International GmbH, part of US biotechnology company Biogen Inc (NASDAQ:BIIB), to develop small molecule protein degraders targeting neurodegenerative diseases.
The collaboration will leverage TRIMTECH's proprietary TRIM21-based targeted protein degradation technology to discover and develop therapies targeting toxic protein aggregates associated with neurodegenerative conditions.
Under the agreement, TRIMTECH is eligible to receive up to USD32m in upfront and research milestone payments, with total potential payments of up to USD411m, plus royalties. If Biogen exercises its option, it will receive a global exclusive licence to the resulting degraders and assume responsibility for further development and commercialisation.
TRIMTECH's technology uses small molecule TRIMTAC and TRIMGLUE degraders designed to access the central nervous system and selectively break down toxic protein aggregates and oligomers implicated in neurodegenerative diseases.
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia